language_icon
EN
HI

Curis Lifesciences Share price

CURIS

117.9

5.90 (5.27%)
Last updated on 23 Apr, 2026 | 15:31 IST
Today's High

118.00

Today's Low

115.50

52 Week Low

83.60

52 Week High

147.90

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Curis Lifesciences Chart

Curis Lifesciences Share Key Metrics

Volume
9000.00
Market Cap
95.32 CR
LTQ@LTP
1000@117.90
ATP
117.18
Var Margin
53.5 %
Circuit Range
89.6-134.4
Delivery %
- %
Value
10.55 L
ASM/GSM
No
Market Lot
1000

Summary

Curis Lifesciences share price stands at ₹117.9 at 23 Apr, 2026 | 15:31. The stock Curis Lifesciences intraday movement has stayed between ₹115.50 and ₹118.00, while on a 52-week basis it has fluctuated from ₹83.60 to ₹147.90.
In terms of trading activity, Curis Lifesciences has recorded a volume of 9000 shares. The Curis Lifesciences has a market cap of ₹8084434. The stock’s Average Traded Price (ATP) stands at ₹11718, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1000, 11790.
The Curis Lifesciences operates within a circuit range of ₹89.6-134.4 – ₹89.6-134.4, with a Value of ₹10.55 L. The Delivery Percentage for the day is -1%. Additionally, Curis Lifesciences currently falls under the No framework, and trades with a market lot size of 1000.

Curis Lifesciences Fundamentals

View More
P/E Ratio

0

P/B Ratio

0

Div. Yield

0

Sector P/E

64.34

Sector P/B

3.51

Sec. Div. Yield

0.57

Curis Lifesciences Resistance and Support

Pivot 112

Resistance

First Resistance

112

Second Resistance

112

Third Resistance

112

Support

First Support

112

Second Support

112

Third Support

112

Curis Lifesciences Shareholding Pattern

View More
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

68.03%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

1.19%

Domestic Institutional Investors

4.35%

Retail

26.43%

Others

0%

Total Promoters
MAR '26
68.03%

Curis Lifesciences Corporate Actions

DateAgenda
2025-12-04Quarterly Results

Curis Lifesciences News

Curis Lifesciences Limited (CURIS)

Curis Lifesciences announces the resignation of Independent Director Ms. Dhruvi Shyam Kapadia, effective April 1, 2026. The resignation is due to her pre-occupancy and increased professional commitments, with no other material reasons cited.
Mar 31 2026 18:03:00

Curis Lifesciences Limited (CURIS)

Dhruvi Kapadia has resigned as an Independent Director of Curis Lifesciences, effective April 1, 2026. The resignation is attributed to pre-occupancy and increased professional commitments, with the company initiating necessary regulatory filings.
Mar 31 2026 18:03:00

Curis Lifesciences Limited (CURIS)

Curis Lifesciences announced the resignation of Independent Director Dhruvi Shyam Kapadia, effective April 1, 2026. Her resignation is attributed to pre-occupancy and increased professional commitments, with no other material reasons cited.
Mar 31 2026 18:03:00

Curis Lifesciences Limited (CURIS)

Curis Lifesciences board approved acquiring a 51% stake in Uninova Lifesciences for ₹20.65 lakh cash, making it a subsidiary. This expands the company's presence in the pharmaceutical industry. The acquisition is expected to be completed within 30 days.
Mar 30 2026 17:03:00

Curis Lifesciences Limited (CURIS)

Curis Lifesciences board approved acquiring a 51% stake in Uninova Lifesciences for ₹20.65 lakh cash, making it a subsidiary. This expands the company's presence in the pharmaceutical industry. The acquisition is expected to be completed within 30 days.
Mar 30 2026 17:03:00

Curis Lifesciences Limited (CURIS)

Curis Lifesciences appointed NGST & Associates as its internal auditor and Sachin Thakkar & Associates as its secretarial auditor, both for a 1-year term. These appointments are effective March 28, 2026, strengthening the company's audit and compliance functions.
Mar 30 2026 16:03:00

Curis Lifesciences Limited (CURIS)

Curis Lifesciences board approved acquiring a 51% stake in Uninova Lifesciences for ₹20.65 lakh cash, making it a subsidiary. This expands the company's presence in the pharmaceutical industry. The acquisition is expected to be completed within 30 days.
Mar 30 2026 16:03:00

Curis Lifesciences Limited (CURIS)

Curis Lifesciences agreed to a strategic investment in Uninova Lifesciences Private Limited, acquiring a 51% equity stake for ₹20.65 lakhs. This move aims to expand its business and diversify its market presence in the pharmaceutical industry.
Mar 30 2026 15:03:00

Curis Lifesciences Limited (CURIS)

Curis Lifesciences agreed to a strategic investment in Uninova Lifesciences Private Limited, acquiring a 51% equity stake for ₹20.65 lakhs. This move aims to expand its business and diversify its market presence in the pharmaceutical industry.
Mar 30 2026 15:03:00
Read More

About Curis Lifesciences

NSE : 759825  
BSE : 0  
ISIN : INE1BZN01016  

Our Company was originally formed and registered as a Partnership Firm under the Partnership Act 1932 (“Partnership Act”) in the name and style of “M/s Loreto Pharmaceutacals” pursuant to a deed of partnership dated June 2 2010. Thereafter " M/s Loreto Pharmaceuticals” was converted from Partnership Firm to a Private Limited Company under the Companies Act 2013 in the name of “Curis Lifesciences Private Limited” and received a certificate of incorporation datedMarch 23 2016 issued by Assistant Registrar of Companies Gujarat. Subsequently our Company was converted into a public limited company and the name of our Company was changed from “Curis Lifesciences Private Limited” to “Curis Lifesciences Limited” vide Special Resolution dated May 6 2024 the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion bearing Corporate Identification Number U24230GJ2016PLC086559 was issued on August 9 2024 by the Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies Central Processing Centre. From year 2010 to 2016 our partnership firm was engaged in the marketing and trading of various pharmaceutical products. As a partnership firm our product portfolio included tablets capsules oral liquids creams ointments injections lotions oral powders and other nutraceuticals products. We procured finished goods from manufacturers and distributed them to various wholesalers and other clients throught the country.MAJOR EVENTS:2011- Started Business by starting a Partnership Firm with two Partners in name of "M/s Loreto Pharmaceutical" by Mr. Dasharathbhai Patel and Mr. Piyush Gordhanbhai Antala.2016- The Partnership Firm got converted into Private Company post conversion and receiving Certificate of Incorporation on March 23rd 2016.2018- The Company received FDA License for manufacturing Pharma products.2019- The Company availed Kenya PPC board approval and approval from Ministry of Health - Republic of Yemen State Good Manufacturing Practices and GLP licence from Local FDA2020- The Company received WHO GMP certificate.2021- The Company received FDA Approval from Philippines during the tragic era of COVID-192022- Renewal of the WHO Certificates and Nigeria NAFDAC Approval2023- Retention of FDA License for manufacturing Pharma products.2025- Conversion From Private Limited into Public Limited company.

Read More

Curis Lifesciences Management

NamePosition
Nikhil PurohitCompany Secretary & Compliance Officer
Dharmesh Dasharathbhai PatelChairman & Managing Director
View More

Curis Lifesciences Similar Stocks

No Data Found

Curis Lifesciences FAQs

The Buying Price of Curis Lifesciences share is 117.9 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Curis Lifesciences stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Curis Lifesciences, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Curis Lifesciences shares is 0. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Curis Lifesciences shares is 0. Useful to assess the stock's value relative to its book value.

To assess Curis Lifesciences’s valuation compare Sector P/E, P/B which are 64.34 & 3.51 with sector averages, along with growth rates and financial metrics.

The Market Cap of Curis Lifesciences is 95.32 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Curis Lifesciences share price is 147.90 & 83.60. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Curis Lifesciences belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost